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Mutational and Transcriptomic Changes Involved in the Development of
Macrolide Resistance in Campylobacter jejuni
Abstract
Macrolide antibiotics are important for clinical treatment of infections caused by Campylobacter jejuni.
Development of resistance to this class of antibiotics in Campylobacter is a complex process, and the dynamic
molecular changes involved in this process remain poorly defined. Multiple lineages of macrolide-resistant
mutants were selected by stepwise exposure of C. jejuni to escalating doses of erythromycin or tylosin.
Mutations in target genes were determined by DNA sequencing, and the dynamic changes in the expression
of antibiotic efflux transporters and the transcriptome of C. jejuni were examined by real-time reverse
transcription-PCR, immunoblotting, and DNA microarray analysis. Multiple types of mutations in ribosomal
proteins L4 and L22 occurred early during stepwise selection. On the contrary, the mutations in the 23S
rRNA gene, mediating high resistance to macrolides, were observed only in the late-stage mutants.
Upregulation of antibiotic efflux genes was observed in the intermediately resistant mutants, and the
magnitude of upregulation declined with the occurrence of mutations in the 23S rRNA gene. DNA
microarray analysis revealed the differential expression of 265 genes, most of which occurred in the
intermediate mutant, including the upregulation of genes encoding ribosomal proteins and the
downregulation of genes involved in energy metabolism and motility. These results indicate (i) that mutations
in L4 and L22 along with temporal overexpression of antibiotic efflux genes precede and may facilitate the
development of high-level macrolide resistance and (ii) that the development of macrolide resistance affects
the pathways important for physiology and metabolism in C. jejuni, providing an explanation for the reduced
fitness of macrolide-resistant Campylobacter.
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Macrolide antibiotics are important for clinical treatment of infections caused by Campylobacter jejuni. Development of resis-
tance to this class of antibiotics in Campylobacter is a complex process, and the dynamic molecular changes involved in this pro-
cess remain poorly defined. Multiple lineages of macrolide-resistant mutants were selected by stepwise exposure of C. jejuni to
escalating doses of erythromycin or tylosin. Mutations in target genes were determined by DNA sequencing, and the dynamic
changes in the expression of antibiotic efflux transporters and the transcriptome of C. jejuniwere examined by real-time reverse
transcription-PCR, immunoblotting, and DNAmicroarray analysis. Multiple types of mutations in ribosomal proteins L4 and
L22 occurred early during stepwise selection. On the contrary, the mutations in the 23S rRNA gene, mediating high resistance to
macrolides, were observed only in the late-stage mutants. Upregulation of antibiotic efflux genes was observed in the intermedi-
ately resistant mutants, and the magnitude of upregulation declined with the occurrence of mutations in the 23S rRNA gene.
DNAmicroarray analysis revealed the differential expression of 265 genes, most of which occurred in the intermediate mutant,
including the upregulation of genes encoding ribosomal proteins and the downregulation of genes involved in energy metabo-
lism andmotility. These results indicate (i) that mutations in L4 and L22 along with temporal overexpression of antibiotic efflux
genes precede andmay facilitate the development of high-level macrolide resistance and (ii) that the development of macrolide
resistance affects the pathways important for physiology andmetabolism in C. jejuni, providing an explanation for the reduced
fitness of macrolide-resistant Campylobacter.
Campylobacter jejuni is a leading cause of diarrhea and one ofthe most common bacterial causes of food-borne illnesses
worldwide (1). Because of the decreasing therapeutic effectiveness
of fluoroquinolones, macrolide antibiotics (e.g., erythromycin
[Ery]) have become more and more important for the treatment
of Campylobacter infections in humans (2, 3). Additionally, some
macrolide antibiotics, including tylosin (Tyl), Ery, and tilmicosin,
are also used in food animal production for both therapeutic and
subtherapeutic purposes (4). As a zoonotic pathogen transmitted
through the food-borne route, Campylobacter is subject to selec-
tion pressure frommacrolide use in both veterinarymedicine and
human medicine. Although the overall prevalence of macrolide-
resistant Campylobacter is relatively low, high incidences of mac-
rolide resistance in Campylobacter have been reported in some
studies (5–9). In order to curb the emergence of macrolide resis-
tance, it is necessary for us to understand how Campylobacter de-
velops resistance to this class of antibiotics.
In Campylobacter, macrolide resistance is mediated by target
mutations and antibiotic efflux (2). Mutations in the L4 and L22
proteins appear tomediate low (MIC, 8 to 16g/ml)-to-interme-
diate (MIC, 16 to 128 g/ml) levels of resistance to Ery, while
mutations in the 23S rRNA gene are associated with high-level
(MIC,256 g/ml) Ery resistance (5, 10, 11). Selection of muta-
tions in the 23S rRNA gene seems to require prolonged exposure
to macrolide antibiotics, suggesting that other mutations or
changes inCampylobactermay be required prior to the occurrence
of the 23S rRNAmutations (2, 10). Active efflux via the CmeABC
multidrug efflux pump is another mechanism that confers resis-
tance tomacrolides onCampylobacter (10, 12, 13). By inactivation
of the CmeABC efflux pump in resistant Campylobacter strains,
previous studies revealed that CmeABC functions synergistically
with the mutations in ribosomal proteins L4 (G74D) and L22
(insertions at position 86 or 98) or the 23S rRNA gene (A2075G)
to confer macrolide resistance (10, 11, 13–15). In Campylobacter,
expression of cmeABC is controlled by CmeR, which binds to the
promoter of cmeABC and regulates the expression of the efflux
operon (16, 17). In addition toCmeABC, previous studies (12, 18)
also suggested that other efflux mechanisms might be associated
with Ery resistance, but the identities of the suspected efflux
pumps are unknown.
Despite the improved understanding of the mechanisms of
macrolide resistance in Campylobacter, the molecular processes
leading to the generation of stable high-level resistance are largely
unknown. Understanding of these molecular events will poten-
tially facilitate the clinical use of antibiotics and targeted control of
macrolide-resistant Campylobacter. Toward this end, we con-
ducted a systemic analysis of the development of macrolide-resis-
tant mutants in culture medium under selection pressure. Multi-
ple lineages of macrolide-resistant C. jejunimutants were selected
in vitro by stepwise exposure of C. jejuniNCTC 11168 and 81-176
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to increasing concentrations of Ery or Tyl. The occurrence of mu-
tations in the 23S rRNA gene (three copies) and the genes encod-
ing ribosomal proteins L4 and L22 was monitored during this
multistep selection process. The dynamic changes in the expres-
sion of four antibiotic efflux genes (cmeB, Cj1687, Cj1257c, and
Cj1375 [cmeG]) in representative lineages were determined by
real-time reverse transcription (RT)-PCR and immunoblotting
(for CmeABC only). DNA microarray analysis was also carried
out with a representative lineage to analyze the global transcrip-
tional changes that occur during the development of macrolide
resistance in C. jejuni.
MATERIALS AND METHODS
Bacterial strains and culture conditions. C. jejuni strains NCTC 11168
and 81-176 were used as the parent stains for in vitro selection of Eryr and
Tylrmutants. Both strains were originally isolated fromhumans, are com-
monly used for laboratory studies, and have been sequenced (accession
no. NC_002163.1 and NC_008787.1). Both strains are susceptible to Ery
and Tyl, and theMICs are 1 and 4g/ml, respectively. TheCampylobacter
strains were grown in Mueller-Hinton (MH) broth or agar at 42°C under
microaerobic conditions (5% O2, 10% CO2, 85% N2).
Susceptibility test. MICs of macrolide antibiotics were measured by
the agar dilutionmethod as recommended by the Clinical and Laboratory
Standards Institute (19). C. jejuni ATCC 33560 was used as the quality
control strain.
Stepwise selection of macrolide-resistant mutants in vitro. Ery and
Tyl were used to select macrolide-resistant mutants in vitro. They were
chosen because Ery is the drug of choice for treating human Campylobac-
ter infections, while Tyl and Ery aremacrolide antibiotics commonly used
in food animal production for therapeutic and subtherapeutic purposes
(4). For the first round of selection, cultures of parent strains C. jejuni
NCTC 11168 and 81-176 were spread on plates containing a series of
increasing concentrations (0.5MIC, 1MIC, and 2MIC) of Ery or
Tyl (11). Following 3 to 5 days of incubation under microaerobic condi-
tions at 42°C, single colonies on the plate with the highest concentration
of the drugs were randomly selected and used for subsequent stepwise
selection. Stepwise selection was performed by transferring and passaging
colonies selected in the first round to MH broth with gradually increased
drug (Ery or Tyl) concentrations. Briefly, each colony picked in the first-
round selection was separately enriched in antibiotic-free MH broth to
the late logarithmic phase to a density of 1 108 CFU/ml, fromwhich 100
l (containing approximately 107 CFU) was transferred to 10 ml MH
broth containing the same concentration of drugs in the first-round se-
lective plates. After 2 to 3 days of incubation, the cells in each culture were
collected as a unit and subjected to MIC determinations. For the next
selection step, 100 l (containing approximately 107 CFU) of the culture
from the previous step was inoculated into 10ml ofMH broth containing
a 2-fold higher concentration of the antibiotic used in the previous step.
During selection with each antibiotic concentration, multiple passages
might be needed to allow adaptation and optimal growth of the selected
mutants. The selective concentration of the antibiotic was gradually in-
creased for each lineage up to the concentration at which the cultures were
not able to grow. A lineage was defined as a series of derivatives selected
from a single colony that was obtained in the first-round selection.
PCR amplification andDNA sequence analysis. The primers used to
amplify the sequences of the 23S rRNA gene, rplD (L4), rplV (L22), and
cmeR along with the promoter of cmeABC are listed in Table 1. All three
copies of the 23S rRNA gene in each of the mutant strains were amplified
and sequenced as described by Gibreel et al. (20). All PCR products were
sequenced in the DNA facility at Iowa State University.
RNA extraction and real-time quantitative RT-PCR (qRT-PCR). To
prepare RNA, C. jejuni cultures were grown on MH plates for 12 h and
harvested with MH broth containing RNAprotect Bacterial Reagent (1:2;
Qiagen, Valencia, CA). RNA extraction, purification, and quantification
were performed as previously described (21). The extracted RNA was
further treated with an On-Column DNase Digestion kit (Qiagen), fol-
lowed by an additional DNase treatment to remove residual DNA con-
tamination. The prepared RNA samples were used as the template for
real-time qRT-PCR and microarray analysis. The relative expression of
four antibiotic efflux transporter genes (cmeB, Cj1687, Cj1257c, and
Cj1375) in four representative lineages (68Ex-1, 68Ex-3, 76Ex-6, and
76Tx-7) was determined by qRT-PCR, which was performed with the
Bio-Rad IQ thermocycler and the iScript One-Step RT-PCR kit with
SYBR green as described previously (21). The primer sets used for specific
genes are listed in Table 1. 16S rRNA was used as a control for normaliza-
tion (22).
SDS-PAGE and immunoblotting. Whole-cell proteins of various
Campylobacter strains were separated by SDS-PAGE and immunoblotted
using anti-CmeA, anti-CmeB, and anti-CmeC antibodies as described
previously (23).
DNA microarray analysis and data analysis. Three Eryr mutants
(68E1-3, 68E8-3, and 68E64-3) in lineage 68Ex-3 were analyzed by mi-
croarray analysis in comparisonwithC. jejuniNCTC11168. Themicroar-
ray analysis slides of C. jejuni (version 1) were obtained from the J. Craig
TABLE 1 Primers used for PCR amplification and real-time RT-PCR
Primer Sequence (5=–3=) Reference
23S rRNA gene
amplification
FI CCCTAAGTCAAGCCTTTCAATCC 20
FII CGTTATAGATACGCTTAGCGGTTATG 20
FIII CATCGAGCAAGAGTTTATGCAAGC 20
CJ-copy-R CTACCCACCAGACATTGTCCCAC 20
Fragment of 23S
rRNA gene
23S-domV-F GTAAACGGCGGCCGTAACTA This study
23S-domV-R GACCGAACTGTCTCACGACG This study
23S-2611F ATGTCGGCTCATCGCATCCTGG 20
23S-2611R CATCCATTACACACCCAGCCTATC 20
Ribosomal protein
L4
L4-F GTAGTTAAAGGTGCAGTACCA This study
L4-R GCGAAGTTTGAATAACTACG This study
Ribosomal protein
L22
L22-F GAATTTGCTCCAACACGC This study
L22-R ACCATCTTGATTCCCAGTTTC This study
CmeR and cmeABC
promoter
cmeR-F TAGAAAAGTATATTTGTATACCCT 16
cmeR-R CGCCACTAACTTGAGGCTTTA 16
Real-time RT-PCRa
16S-F TACCTGGGCTTGATATCCTA 21
16S-R GGACTTAACCCAACATCTCA 21
CmeB-F ACGATTCAACCTTTTCCCAGC This study
CmeB-R TTTGCTACTTGAGCAATCGCTTC This study
Cj1687-F TGGTGGTTTGGACTCTTTCTGGGA This study
Cj1687-F TCTCTGCGATTAAAGCCACCACGA This study
Cj1375-F GCTTTACCACGATTTTCTTCTGTGA This study
Cj1375-R TACACCATGCTTTTAGGAAGAATGC This study
Cj1257c-F ATCGCCGTGATAGCGCCTAAAGAA This study
Cj1257c-R GCCACCAAACAAAGGCCCAAGTAA This study
a Sequences and gene names are based on C. jejuni NCTC 11168.
Hao et al.
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Venter Institute. For each microarray analysis slide, a pair of cDNA sam-
ples prepared fromNCTC 11168 and a mutant culture, respectively, were
cohybridized. Four hybridizations using four independent RNA samples
were performed for each pair of C. jejuni cultures. cDNA labeling, prepa-
ration, and hybridization were performed following the protocols from
the J. Craig Venter Institute. Data collection and normalization were per-
formed as previously described (17). After statistical analysis, the set of p
values was converted to q values to control the false-discovery rate. For
this study, genes with a q value of 0.1 and a change of 1.5-fold were
identified as being differentially expressed by the resistant and wild-type
strains. Differentially expressed genes were first classified on the basis of
the genomic annotation at the Sanger Center and then subjected to clus-
tering analysis (K-means/medians clustering [KMC]) and hierarchical
clustering (HCL) analysis using Multiexperiment Viewer (MeV v4.4).
Microarray data accession number. Themicroarray data obtained in
this study have been deposited in the NCBI Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/database) and assigned ac-
cession number GSE17881.
RESULTS
Lineages of the selected macrolide-resistant mutants. Three in-
dividual colonies (68E-1, 68E-2, and 68E-3) of parent strain C.
jejuniNCTC 11168were randomly selected on plates containing 1
g/ml Ery in the first-round selection and subjected to stepwise
selection to obtain three representative lineages of Eryr mutants
(68Ex-1, 68Ex-2, and 68Ex-3). Similarly, one representative col-
ony (76E-6) of parent strain C. jejuni 81-176 was selected on a
plate with 2g/ml Ery in the first-round selection and one lineage
of Eryr mutants (76Ex-6) was obtained after stepwise selection.
The characteristic features of the four lineages are described in
Table 2.
By using Tyl as the selective agent, four individual colonies
(68T-1, 68T-2, 68T-3, and 68T-4) of parent strainC. jejuniNCTC
11168 were selected on plates with 4 g/ml Tyl and one colony
(76T-7) ofC. jejuni 81-176was selected on plates with 8g/ml Tyl
in the first round of selection. After stepwise selection, five repre-
sentative lineages of Tylr mutants (68Tx-1, 68Tx-2, 68Tx-3,
68Tx-4, and 76Tx-7) were obtained; their characteristic features
are listed in Table 3.
Dynamic changes inpointmutations in target genesandpro-
teins. As shown in Tables 2 and 3, multiple mutations were ob-
served in the target genes (the 23S rRNA gene, the genes for ribo-
somal proteins L4 and L22, and cmeR). Overall, the mutations in
the genes for L4 and L22 occurred earlier in the stepwise selection
process, while the mutations in the 23S rRNA gene occurred later
in the selection process and were associated with high-level resis-
tance to Ery (MIC,256 g/ml).
Six different changes in ribosomal protein L4 were observed in
TABLE 2 Characteristics of C. jejuni mutants selected by Ery
Lineagea and strainb
MIC (g/ml)
Mutation in 23S rRNA genec Change in protein L4 Change(s) in protein L22 Mutation in cmeREry Tyl
Parent, NCTC 11168 1 4 —d — —
68Ex-1
68E1-1 4 8 — — A88E —
68E4-1 32 256 — — A88E Del490A
68E8-1 64 128 — — A88E Del490A
68E32-1 256 128 — G67V A88E Del490A
68E64-1 512 256 C2627A (3) G67V A88E Del490A
68Ex-2
68E1-2 4 8 — 59-G-60 —
68E4-2 32 128 — 59-G-60 G86E —
68E8-2 64 128 — 59-G-60 A84D, G86E —
68E32-2 128 128 — 59-G-60 A84D, G86V —
68E64-2 512 256 — 59-G-60 A84D, G86V —
68Ex-268Ex-3
68E1-3 4 16 — R72I — —
68E4-3 64 64 — R72I V100L H174N
68E8-3 128 256 — R72I 91-S-92 H174N
68E32-3 512 512 — R72I — H174N
68E64-3 512 512 A2074C (3) R72I — H174N
Parent, 81176 1 4 — — — —
68Ex-268Ex-376Ex-6
76E2-6 32 64 — — — —
76E8-6 256 512 A2074C (2) — — —
76E64-6 512 512 A2074C (3) — — —
a The lineages are named according to the parent strain and the antibiotic used for selection. 68 and 76 indicate that the parent strains are 11168 and 81-176, respectively, E
represents selection by Ery, x depicts the various concentrations used for selection, and the last number indicates the lineage number.
b The strains in the lineages are named similarly to the lineages, except that x is replaced by the actual antibiotic concentration from which the mutant was selected.
c Each number in parentheses is the number of mutated copies of the 23S rRNA gene.
d —, no mutations detected.
Development of Macrolide Resistance in Campylobacter
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the macrolide-resistant mutants selected (Tables 2 and 3). The
Gly-to-Val (G57V) and Gly-to-Asp (G57D)modifications identi-
fied at position 57 in L4were previously reported byCaldwell et al.
(11). Four other mutations in ribosomal protein L4, including
R72I, G67V, and A71D and the insertion of a glycine at position
59, represent new mutations identified in this study. In a given
lineage, only one type of mutation was observed in L4.
Modifications at positions 84, 86, and 88 were frequently ob-
served mutations in ribosomal protein L22 in the macrolide-re-
sistant mutants (Tables 2 and 3). G86E and A88E were more fre-
quent than other types of mutations in the mutants analyzed. In
lineage 68Ex-2, the G86E mutation in L22 was switched to G86V
and the modification at position 86 coexisted with A84D (Table
2). With respect to the 23S rRNA gene, the A2074Cmutation was
observed in the high-level Eryr mutants of two lineages (68Ex-3
and 76Ex-6). In 68E64-3, the A2074C change was present in all
three copies of the 23S rRNA gene. In the 76Ex-6 lineage, the
A2074C transversion occurred earlier in themutant selection pro-
cess. This point mutation was present in only two of the three
copies of the 23S rRNAgene in 76E8-6 but in all three copies of the
23S rRNA gene in 76E64-6 (Table 2). Interestingly, the high-level
Eryrmutant (68E64-1) in lineage 68Ex-1 displayed a different type
of point mutation in the 23S rRNA gene with a C¡A point mu-
tation at position 2627 (equivalent to position 2611 in Escherichia
coli). In one of the lineages selected with Ery (68Ex-2), stepwise
selection failed to select mutants containing mutations in the 23S
rRNA gene (Table 2), while none of the Tyl-selected mutants dis-
played point mutations in the 23S rRNA gene (Table 3).
Dynamic changes in the expressionof antibiotic effluxgenes.
The qRT-PCR results (Fig. 1) showed that there was a general
trend for increased expression of the four efflux genes (cmeB,
Cj1687, Cj1257c, and Cj1375) in the lineages examined (68Ex-1,
68Ex-3, 76Ex-6, and 76Tx-7). In lineage 68Ex-1 (Fig. 1B), the
most obvious change was a drastic increase in the expression of
cmeB and Cj1687 in 68E4-1, and the magnitudes of overexpres-
sion of the two efflux genes subsequently declined in the later-
stage mutants of the lineage. In the 68Ex-3 lineage (Fig. 1A), all
four of the efflux genes tested were upregulated and the magni-
tudes of upregulation of cmeB, Cj1257c, and Cj1687 were greater
than that ofCj1375. In lineage 76Ex-6 (Fig. 1C), overexpression of
cmeB was observed in 76E2-6 and 76E8-6, while the expression
level of cmeB in 76E64-6 returned to the level of the parent strain,
TABLE 3 Characteristics of C. jejuni mutants selected by Tyl
Lineagea and strainb
MIC (g/ml)
Mutation in 23S rRNA gene Change in protein L4 Change(s) in protein L22 Mutation in cmeREry Tyl
Parent, NCTC
11168
1 4 —c — —
68Tx-1
68T4-1 4 8 — — A88E
68T16-1 32 256 — R72I A88E H174N
68T32-1 64 256 — R72I A88E H174N
68T128-1 128 256 — R72I A88E H174N
68Tx-2
68T4-2 4 8 — — —
68T16-2 128 256 — G57V — —
68T32-2 256 512 — G57V G86E —
68T128-2 128 256 — G57V G86E —
68 Tx-3
68T4-3 2 8 — — — —
68T16-3 32 256 — A71D — S117Y
68T32-3 64 512 — A71D A88E S117Y
68T64-3 16 256 — A71D A88E S117Y
68Tx-4
68T4-4 2 8 — — — —
68T8-4 16 64 — A71D — —
68T16-4 32 128 — A71D A88E G204L
68T32-4 64 256 — A71D A88E G204L
68T64-4 128 512 — A71D A88E, G86V G204L
Parent, 81176 1 4 — — — —
76Tx-7
76T8-7 8 32 — — — —
76T16-7 32 128 — G57D G86E —
76T32-7 64 256 — G57D G86E —
a See Table 2 footnote a for an explanation of the lineage names. T represents selection by Tyl.
b See Table 2 footnote b for an explanation of the strain names.
c —, no mutations detected.
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C. jejuni 81-176. In lineage 76Tx-7 (Fig. 1D), cmeB and Cj1687
were significantly overexpressed and the change was especially
obvious for Cj1687 in 76T16-7. Overall, there was a general trend
for the overexpression of the efflux genes to be temporarily up-
regulated in the mutants with intermediate-level resistance and
subsequently decline in the later-stage mutants.
Immunoblotting analysis further showed the change in Cme-
ABC expression in the lineages (Fig. 2). In each lineage, the pro-
FIG 1 Differential expression of four efflux genes in selected mutant strains in four different lineages. The data were generated by real-time RT-PCR in
comparison with the parent strain (NCTC 11168 or 81-176).
FIG 2 Immunoblotting analysis of CmeABC expression in selected strains in four different lineages. In panel A, numbers 1, 2, 3, 4, 5, and 6 represent C. jejuni
NCTC 11168, 68E1-3, 68E4-3, 68E8-3, 68E32-3, and 68E64-3, respectively. In panel B, numbers 1, 2, 3, 4, 5, and 6 correspond to C. jejuniNCTC 11168, 68E1-1,
68E4-1, 68E8-1, 68E32-1, and 68E64-1. In panel C, numbers 1, 2, 3, and 4 correspond to C. jejuni 81-176, 76E2-6, 76E8-6, and 76E64-6. In panel D, numbers 1,
2, 3, and 4 correspond to C. jejuni 81-176, 76T8-7, 76T16-7, and 76T32-7. Cell envelopes prepared from each strain were blotted with polyclonal antibodies to
CmeA, CmeB, and CmeC. The same amount of total proteins was loaded in each lane. Prestained molecular mass markers (lane M; Bio-Rad) were used to
estimate the sizes of the proteins (shown in kilodaltons). The positions of CmeA, CmeB, and CmeC are indicated.
Development of Macrolide Resistance in Campylobacter
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duction of CmeABC proteins increased during the mutant selec-
tion process. For example, the CmeB protein was significantly
overproduced in 68E4-3, 68E8-3, and 68E32-3 (lanes 3, 4, and 5 in
Fig. 2A) compared with the wild-type strain. Likewise, a signifi-
cant increase in CmeB production was observed in 76E8-6 (lane 3
in Fig. 2C).
Identification ofmutations in cmeR. Since cmeABCwas over-
expressed in themutant selection process (Fig. 1 and 2), we further
determined if any mutations occurred in cmeR and the promoter
of cmeABC that might explain the overexpression of cmeABC.
Three different types of point mutations (H174N, S117Y, and
G204L) and a deletion (del490A) were detected in cmeR in some
mutant strains of five different lineages, including 68Ex-1, 68Ex-3,
68Tx-1, 68Tx-3, and 68Tx-4 (Tables 2 and 3). The del490A nucle-
otide deletion would cause a frameshift and truncation of the
CmeR open reading frame, whichmay explain the overexpression
of cmeB in lineage 68Ex-1 (Fig. 1 and 2). The H174N substitution
in CmeR also occurred concomitantly with the observed overex-
pression of cmeB in lineage 68Ex-3, suggesting that the H174N
mutation may affect the function of CmeR. No mutations in the
promoter of cmeABC were observed in any of the Eryr mutants.
Dynamic changes in the transcriptome duringmutant selec-
tion. To examine the global change at the transcriptional level in
themutant selection process, three Eryr mutants (68E1-3, 68E8-3,
and 68E64-3) of lineage 68Ex-3 were subjected to microarray
analysis in comparisonwithC. jejuniNCTC11168. The transcrip-
tional abundance of 265 genes was altered in at least one of the
three strains. In 68E1-3, only nine genes were found differentially
expressed in comparison with the parent strain. However, in
68E8-3, 85 genes were upregulated and 124 genes were downregu-
lated, and in 68E64-3, 52 genes were upregulated and 93 genes
were downregulated (see Fig. S1 and Table S1 in the supplemental
material). Of the 265 genes, 86 were also changed in 68E8-3 and
68E64-3 (see Fig. S1 and Table S1). Only five genes showed differ-
ential expression in all three mutant strains, of which Cj0561c,
Cj0365c (cmeC), and peb3 were upregulated while Cj1465 and
Cj1357c were downregulated (see Table S1).
After KMCanalysis, the 265 genes were grouped into four clus-
ters, numbered 1, 2, 3, and 4 (Fig. 3). The clusters clearly visualized
the trends of transcriptional changes during the development of
macrolide resistance in C. jejuni. Cluster 1 includes 64 genes the
expression of whichwas not changed in 68E1-3 but upregulated in
68E8-3; and then in 68E64-3, their overexpression was reduced,
with many returning to a near-wild-type level. On the contrary,
the 122 genes in cluster 2 were downregulated in 68E8-3 but the
magnitudes of downregulation were reduced in 68E64-3. Cluster
3 includes 40 genes whose expression level continuously increased
in the lineage as macrolide resistance increased. The 39 genes in-
cluded in cluster 4 showed little change in expression in 68E1-3
and 68E8-3 but were downregulated in highly resistant strain
68E64-3. Additionally, from the order or distance of the three
strains exhibited in the HCL-Tree (Fig. 3) in each cluster, it can be
seen that the differentially expressed genes in 68E8-3 are charac-
teristic changes in clusters 1 and 2, while the transcriptomic alter-
ations in 68E64-3 better represent the characteristic changes in
clusters 3 and 4.
The 64 genes in cluster 1 include those encoding broad regula-
tory functions (perR, cetB, and cbrR), efflux pumps (Cj1173, cmeB,
cmeC, and Cj0035c), ribosomal proteins (rpmC, rpsCEJ, and rpl-
CDEMW), aminoacyl tRNA synthetases (fmt and cysS), DNA rep-
lication/protein translation-associated proteins (gidA, ligA, def,
and pnp), and small-molecule metabolism (tkt, hisL, ilvE, nrdB,
bioB, panBD, and fabF). Additionally, the cluster includes genes
encoding membrane proteins (Cj1170c, Cj0378c, and Cj0124c),
surface polysaccharides (Cj1425c,Cj1430c, and lpxB), periplasmic
proteins (Cj0561c,Cj1169c,Cj0515, andCj1021c), ABC transport-
ers (livHJG and Cj0469), a molybdenum transport system
(modBC), and amino acid transporters, as well as other transport-
ers (Cj0982c, Cj0025c, Cj1389, and Cj1097).
Cluster 2 includes genes encoding broad regulators (Cj0448
andCj1491c), ribosomal proteins (rplI and rpsA), membrane pro-
teins (Cj1493c, Cj1026c, pal, Cj0423, Cj0176c, porA, and Cj0830),
surface polysaccharides (Cj1423c and kpsM), flagellar proteins
(flgBCGG2EE2KI, fliDE, and flaABCDG), nutrient transport/bind-
ing proteins (peb1A, chuAD, corA, cfrA, lctP, dcuA, kgtP, Cj0486,
Cj0654c, and exbB2D2), chaperons or heat shock proteins (clpB,
cbpA, hrcA, dnaK, grpE, and groEL), and detoxification enzymes
(ahpC and Cj0358). Additionally, the cluster includes genes in-
volved in carbon compound degradation (galU and pta), energy
metabolism (pyk, gltA, sdhAB, acnB, and frdABC), respiration
(gpsA, Cj1357c, Cj1358c, Cj0074c, Cj0075c, Cj0265c, fdxA, and na-
pAGH), central intermediary metabolism (ppa, gltB, aspA, and
uxaA), amino acid biosynthesis (glnA, argG, serA, aroQ, and leuB),
nucleoside biosynthesis (purD and dut), and fatty acid biosynthe-
sis (Cj1537c).
Many of the 40 genes in cluster 3 are involved in protein syn-
thesis, including those for ribosomal proteins (rplAJTLFPRNVXO
and rpsDPNSQ) and elongation factor Tu (tuf). Additionally, the
cluster includes genes for a transcriptional regulator (Cj0440c),
membrane proteins (Cj1658,Cj0544, andCj1013c), a surface poly-
saccharide (Cj1136), miscellaneous periplasmic proteins (Cj0420,
Cj1540, and peb3), and cation transporter/binding proteins (ceuE
and Cj0175c), as well as genes involved in energy metabolism
(oorC, Cj1153, and atpCDE), amino acid biosynthesis (metEY),
and peptide secretion (secY and lspA).
Cluster 4 includes genes encoding a transcriptional regulator
(Cj1000), transport/binding proteins (Cj0012c,Cj0045c, pstC, and
tonB2), chaperons or heat shock proteins (groES and hspR), and a
chemotaxis histidine kinase (cheA). Additionally, the cluster in-
cludes genes involved in peptide secretion (Cj1471c), energy me-
tabolism (sdhC, gpsA, Cj0037, Cj0874c, and atpB), central inter-
mediary metabolism (ppk and cysQ), amino acid biosynthesis
(argG and trpF), nucleoside biosynthesis (pryG and upp), amino-
acyl tRNA synthesis (glyS), DNA replication (mutY), and the bio-
synthesis of membrane or surface structures (Cj0629, Cj0341c,
Cj0455c, Cj1316c, neuB2C2, fliA, Cj1275c, and Cj0004c).
Several representative differentially expressed genes (Cj0561c,
Cj1199, Cj1013c, flgI, and sdhA) identified by DNA microarray
analysis were further confirmed by qRT-PCR. Inmost of the cases,
the qRT-PCR data confirmed the up- or downregulation detected
by microarray analysis (data not shown). The relative n-fold
changes inCj0561c andCj1013c detected by qRT-PCRweremuch
greater than those detected by microarray analysis (data not
shown).
DISCUSSION
In this study, the dynamic changes in target gene mutations, ex-
pression of antibiotic efflux genes, and the global transcriptome
were analyzed during the process ofmacrolide resistance develop-
ment in Campylobacter. The findings provide a glimpse into the
Hao et al.
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development of macrolide resistance in C. jejuni, which involves
mutations in L4 and L22 preceding the occurrence ofmutations in
the 23S rRNA gene, temporal upregulation of multidrug efflux
genes, and transcriptomic changes inmetabolic pathways and cel-
lular processes. These results indicate a complex adaptive process
involved in the development of macrolide resistance in Campylo-
bacter.
It is known that modifications in the large loop of the L4 pro-
FIG 3 HCL analysis of C. jejuni genes differentially expressed in the three strains (68E1-3, 68E8-3, and 68E64-3) in lineage 68Ex-3. For each of the four clusters,
hierarchical clustering was performed both on the genes and on the strains to visualize the relationships among the genes and strains, respectively. Four clusters are
presented in fourdifferentpanels. For eachcluster, the color scale shows then-fold change rangeofup- anddown-regulatedgenes.The threemutant strains are indicated
at the top of each panel.
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tein (amino acids [aa] 55 to 77) (24, 25) and in the highly con-
served large loop of the L22 protein (aa 78 to 98) (26, 27) were
associated with macrolide resistance in various bacteria. In this
study, several mutations in ribosomal proteins L4 (R72I, G67V,
A71D, and the insertion of a glycine at position 60) and L22
(A84D, G86E, G86V, and A88E) were observed in macrolide-re-
sistant mutants (Tables 2 and 3), indicating that mutations in the
ribosomal proteins are actively involved in the adaptation tomac-
rolide selection in Campylobacter. It appears that some modifica-
tions in ribosomal proteins L4 (R72I) and L22 (A88E and G86E)
may facilitate the development of high-level resistance to macro-
lides in Campylobacter, because they were frequently observed in
derivatives with different levels of macrolide resistance (5). How-
ever, somemutations in L4, such asG57D,G57V, andA71D, seem
to impede the emergence of highly resistant mutants (mutations
in the 23S rRNA gene), because subsequent selection of mutants
carrying such mutations did not further increase the Ery MIC
(Table 3). A similar phenomenon was observed in previous stud-
ies (11, 28). These observations suggest that mutations in L4 and
L22 are commonly involved in the development of macrolide re-
sistance, but certainmutations in the ribosomal proteinsmight be
incompatible with the mutations in the 23S rRNA gene, prevent-
ing the emergence of highly resistant mutants.
Interestingly, there were some differences in the mutations se-
lectedwith Tyl and Ery. ThemutationsG57D,G57V, andA71D in
L4 were observed only in mutants selected with Tyl (Tables 2 and
3). On the other hand, the mutations in the 23S rRNA gene oc-
curred only in mutants selected with Ery, and selection with Tyl
was not able to obtain mutants highly resistant to Ery (MIC,
512). A previous study also found that Tyl failed to select Cam-
pylobactermutants that harbormutations in the 23S rRNA gene in
culture medium (11). However, Eryr mutants that harbored mu-
tations in the 23S rRNA gene developed in C. jejuni-infected
chickens fed a growth-promoting dose of Tyl for a prolonged time
(10). These observations suggest that the selection environment
influences the development of macrolide-resistant mutants. Ad-
ditionally, Ery is a 14-membered macrolide while Tyl is a 16-
membered macrolide with slightly different ribosome binding
sites (29). Thus, the structural variations between the two antibi-
otics might also contribute to the differences in the mutants se-
lected.
C. jejuni has three copies of the rrn operon (20, 30, 31). Multi-
ple studies have identified Eryr mutants (Ery MIC, 64 g/ml)
that carried the A2074C or A2075G mutation in two or three
copies of the 23S rRNA gene (11, 20, 28, 32, 33). A previous study
reported that the A2074G mutation in only one copy of the 23S
rRNA gene resulted in a moderate increase in the Ery MIC (8
g/ml) for aCampylobacter colimutant that was selected with Ery
(10). In this study, the A2074C transversion was observed in at
least two copies of the 23S rRNAgene (Table 2). In lineage 76Ex-6,
further selection of the mutant with the A2074C transversion in
two copies of the 23S rRNA gene led to the occurrence of the same
mutation in all three copies and a concurrent increase in the mac-
rolide MICs (Table 2). Together, these observations suggest that
the number of mutated copies of the 23S rRNA gene increasingly
reduces the susceptibility ofCampylobacter to macrolide antibiot-
ics but a mutation in at least two copies of the 23S rRNA gene is
required for high-level resistance to macrolides.
In Campylobacter, the frequency of emergence of single-step
macrolide-resistant mutants is quite low (109), and de novo
development of macrolide-resistant mutants requires prolonged
exposure to the antibiotic (10), suggesting that multiple muta-
tions are required to raise theMICs ofmacrolide antibiotics. Dur-
ing the stepwise selection process in this study, 107 CFU of the
organisms were inoculated into 10 ml of MH broth with an ele-
vated antibiotic concentration. This inoculum was well below the
number required for the presence of preexisting multiple muta-
tions. Thus, multiple passages were required during certain selec-
tion steps to allow the selection of newmutations that support full
growth at an elevated antibiotic concentration. Despite the differ-
ence between this methodology and the model of selection in an
animal host (10), the evolutionary pathways appear to be similar,
i.e., involving mutations in L4 and L22, followed by the occur-
rence ofmutations in the 23S rRNA gene. It should be pointed out
that this study measured mutations in only a few target genes.
Mutations in other chromosomal genes likely also contribute to
the development of macrolide resistance in Campylobacter and
were not measured in this work.
The overexpression of CmeABC in the stepwise selection pro-
cess was consistently shown with three techniques, including
qRT-PCR, immunoblotting, and microarray analysis (Fig. 1, 2
and 3), suggesting that the differential expression of this predom-
inant antibiotic efflux system facilitates the development of mac-
rolide resistance. Besides cmeABC, two major facilitator super-
family (MFS) transporters (Cj1687 andCj1257c) were particularly
upregulated as detected by qRT-PCR (Fig. 1), while the microar-
ray analysis result revealed the significant upregulation of a small
multidrug resistance (SMR) superfamily member transporter
(Cj1173) and an MFS transporter (Cj0035c) in 68E8-3 (Fig. 3,
cluster 1). Although a previous study (34) found that insertional
inactivation of Cj1687, Cj1257c, Cj1174, and Cj0035c did not alter
the susceptibility of C. jejuni to Ery, the upregulation of these
efflux transporters during stepwise selection suggests that they
may play a role in the development of macrolide resistance.
Cj1375 (cmeG) is another MFS transporter of C. jejuni and was
shown to confer resistance to antibiotics and oxidative stress;
however, overexpression of cmeG did not increase resistance to
Ery (35). In this study, cmeGwas upregulated in some lineages but
the change was not as obvious as that in other efflux genes exam-
ined.
An interesting observation of this study is that the overexpres-
sion of the antibiotic efflux genes was most significant in the in-
termediately resistant mutants and the level of overexpression ac-
tually declined in the late-stage mutants (Fig. 1, 2, and 3). This
finding suggests that the enhanced expression of the efflux genes is
temporarily required to facilitate the development of highly resis-
tant mutants, in which mutations in the 23S rRNA gene or other
changes stabilize the resistance phenotype. The interplay of the
antibiotic efflux pump CmeABC and ribosomal protein L4/L22
was also observed in previous studies in which it was found that
the efflux system acted synergistically with some modifications in
ribosomal proteins L4 and L22 to mediate intermediate-level
macrolide resistance and facilitate the development ofmutation in
the 23S rRNA gene (14, 15). Together, these observations clearly
indicate that the dynamic change in efflux gene expression inter-
acts with target mutations to facilitate Campylobacter adaptation
to the selection pressure from macrolide treatment.
In Campylobacter, expression of cmeABC is controlled by
CmeR, which functions as a repressor of cmeABC (16). The over-
expression of cmeABC during stepwise selection could be partly
Hao et al.
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explained by mutations in CmeR, such as the nucleotide deletion
at 490A and theH174N change in the protein (Tables 2 and 3). On
the basis of the sequence and crystal structure of CmeR, these
mutations are located in the C-terminal domain of CmeR (36–
39). The deletion at 490A is expected to truncate the CmeR pro-
tein, whichmay explain the significant upregulation of cmeABC in
the 68Ex-1 lineage (Table 2; Fig. 1B and 2B). The H174 residue of
CmeR is in the ligand-binding pocket of CmeR and is important
for the interaction with various ligands, including bile acid, glyc-
erol, and drugs (38, 39). Thus, the H174N mutation likely affects
the function of CmeR and leads to the upregulation of cmeABC in
the 68Ex-3 lineage (Table 2; Fig. 1A and 2A). This notion is further
supported by the fact that Cj0561cwas also upregulated in lineage
68Ex-3 (Fig. 3). Cj0561c encodes a putative periplasmic protein
and is subject to direct regulation by CmeR (17). Thus, overex-
pression of Cj0561c further suggested that the H174N mutation
altered the function of CmeR. The direct impact of the CmeR
mutations on the function of CmeR remains to be determined in
future studies.
It should be pointed out that the overexpression of cmeABC
cannot be totally explained by mutations in CmeR, as some lin-
eages (such as 76Ex-6 and 76Tx-7) did not harbor any mutations
in CmeR (or the promoter of cmeABC) but showed overexpres-
sion of cmeABC (Tables 2 and 3; Fig. 1 and 2). Additionally, al-
though the same CmeR mutation (such as in lineages 68Ex-1 and
68Ex-3) existed in the late-stage mutants, the levels of cmeABC
overexpression declined in these highly resistant mutants. These
observations suggest that a CmeR-independent mechanism also
modulates the expression of cmeABC. Indeed, a recent study indi-
cated that CosR, an oxidative stress regulator, serve as the second
repressor of cmeABC (40). Thus, any mutations that affect the
function of CosR would potentially modulate the expression of
cmeABC. It is also likely that the accumulation of other mutations
offsets the need for cmeABC overexpression in late-stagemutants.
These possibilities await further examination in future studies.
The microarray analysis produced several interesting findings.
First, few genes were differentially expressed in the first-step mu-
tant, while most of the differential gene expression was observed
in the intermediate-level-resistantmutant (68E8-3) and the num-
ber of differentially expressed genes and the magnitudes of differ-
ential expression were significantly reduced in highly resistant
strain 68E64-3, which contained the A2074Cmutation in all three
copies of the 23S rRNA gene. This finding strongly suggests that
global changes at the transcriptomic level are temporarily in-
volved in the development of macrolide-resistant mutants and
that there is a tendency to restore the transcriptome to the wild-
type state in the stable highly resistant mutant. Second, a large
number of genes encoding ribosomal proteins (rplJPTXOLRFN-
VAWCDME, rpsPNSCDQEJ, and rpmC) were upregulated. Mac-
rolides target the bacterial ribosome and inhibit protein synthesis,
and the resistance-associatedmutations in L4 andL22 alleviate the
inhibitory effect of the antibiotics but might reduce the efficiency
of protein synthesis (5). Thus, upregulation of the protein synthe-
sis machinery is likely a compensatory response to the reduced
rate of protein synthesis in the mutants. Third, a large number of
genes involved in the heat shock response, motility, and energy
metabolism were significantly downregulated in the macrolide-
resistant mutants, suggesting that the development of macrolide
resistance inC. jejuni profoundly impactsCampylobacter physiol-
ogy and may result in a growth burden and fitness cost. Indeed,
several recent studies found thatmacrolide-resistantCampylobac-
ter shows a significant fitness cost in vitro and in vivo and is out-
competed by susceptible Campylobacter in the chicken host in the
absence of antibiotic selection pressure (41–44).
In summary, this study has revealed dynamic changes in target
gene mutations and differential gene expression during the step-
wise selection of macrolide resistance in Campylobacter. Particu-
larly, the results discovered a temporal overexpression of antibi-
otic efflux pumps in the selection process, which interacts with
mutations in L4 and L22 and facilitates the development of stable
and highly resistantmutants. Additionally, the study also revealed
that there is an intermediate “chaos” state in terms of global gene
expression in the development ofmacrolide resistance and further
adaptation to antibiotic selection appears to favor the return of the
transcriptome to the wild-type state in highly resistant mutants.
These findings depict a complex process involving interplay be-
tween target mutations and differential gene expression and pro-
vide new insights into the molecular mechanisms underlying the
development of macrolide resistance in C. jejuni.
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